



PATENT

Our Docket: P-IMM 1003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
Robbins and Tritz

Serial No: 09/696,791

Filed: October 25, 2000

Title: RIBOZYME THERAPY FOR
THE TREATMENT OF
PROLIFERATIVE SKIN AND
EYE DISEASES

Commissioner for Patents
Alexandria, VA 22313-1450

) Group Art Unit: 1635

) Examiner: K. Lacourciere

) I hereby certify that this correspondence
) is being mailed first class to the United
) States Patent and Trademark Office on
) November 26, 2003.

David Spolter
David Spolter, Reg. No. 36,933

November 26, 2003

Date of Signature

STATEMENT

Applicants acknowledge the Notice of Allowance of this case, mailed November 5, 2003. Applicants also acknowledge the Examiner's Amendment, mailed along with the Notice.

In the Amendment, the Examiner refers to an interview with Applicants' representative on October 28, 2003. Applicants wish to clarify that at this interview, as well as at previous interviews, Applicants corrected an unintentional error in Applicants' declaration, which was mailed on April 1, 2003.

Specifically, the data submitted in the declaration that referred to SEQ ID NO:4385 actually refers to a sequence that is slightly different than SEQ ID NO:4385. More particularly, SEQ ID NO:4385 has a "c" in

the eighth position from the left. In the data presented in the declaration, the corresponding position is a "c" (in *italics*), which means this position is methylated.

The Examiner understood this correction and allowed the claims with this understanding. As pointed out to the Examiner, because the sequence introduced in the declaration is slightly different, it exemplifies use of another species within the scope of the allowed genus.

Respectfully submitted,

Date: November 26, 2003

David I. Spolter

David I. Spolter

Registration No. 36,933

Telephone: (858) 459-2934

Facsimile: (858) 459-0698

LAW OFFICE OF DAVID SPOLTER
1590 Coast Walk
La Jolla, California 92037